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Poster Session I 63(n 5 81) or a double (n 5 23) unrelated UCBT for an advanced
lymphoid malignancy. Sixty-three patients had a non-Hodgkin
lymphoma (18 diffuse large B-cell lymphoma, 10 follicular lym-
phoma, 8 mantle cell lymphoma, 8 peripheral T-cell lymphoma,
14 other T-cell lymphomas, 5 other B-cell lymphomas), 28 had
Hodgkin lymphoma, and 13 had B-cell chronic lymphocytic leuke-
mia (CLL). The majority of patients (85%) had advanced disease
(relapse, refractory disease, partial remission or $3rd complete re-
mission), and 54% had a prior autologous transplant. Based on an-
tigen-level HLA-A and B and allele-level HLA-DRB1 typing, cord
blood units were matched (9%) or mismatched at 1 (26%), 2 (59%)
or 3 (6%) antigens. The median number of cells infused was 2.4 
107 total nucleated cells (TNC)/kg for single transplants and 3.1 
107 TNC/kg for double transplants. Conditioning regimen varied
according to the transplant center, but 62% received a reduced-in-
tensity conditioning (RIC). GVHD prophylaxis was achieved with
cyclosporin and MMF in 48% of cases. Median follow-up time
for survivors was 14 months. The probability of engraftment at
day 60 was 86%, with a median time to engraft of 20 days (3–54).
In a multivariate analysis, a higher cell dose (2.5  107 TNC/kg)
was significantly associated with the neutrophil engraftment (p 5
0.04). Grade II-IV acute graft-versus-host disease (GVHD) was ob-
served in 24% of the patients. Transplant-related mortality (TRM)
was 34% at 6 months. In a multivariate analysis, TRM was signifi-
cantly lower for patients with B-cell malignancies (B-cell non-
Hodgkin lymphomas and CLL) as compared to those with Hodgkin
or T-cell lymphomas (21% vs. 49%; p 5 0.005), patients who re-
ceived TBI (25% vs. 49%; p 5 0.04). Disease free survival (DFS)
at 1 year was 40%. In a multivariate analysis, DFS was significantly
better for patients with B-cell malignancies (54% vs. 21%; p 5
0.006) and patients who received TBI (49% vs. 23%; p 5 0.001).
In conclusion, UCBT is a valuable alternative for patients with ad-
vanced non-Hodgkin lymphoma and CLL. B-cell malignancies and
the use of TBI are associated with a significantly better outcome.
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CHARACTERISTICS AND OUTCOMES OF MULTIPLE MYELOMA PATIENTS
ON HEMODIALYSIS UNDERGOING AUTOLOGOUS STEM CELL TRANS-
PLANTATION: ANALYSIS OF THE US RENAL DATABASE SYSTEM
Weiss, B.M.1, Neff, R.T.2, Verma, P.3, Agodoa, L.4, Abbott, K.C.2 1Wal-
ter Reed Army Medical Center, Washington, DC; 2Walter Reed Army
Medical Center, Washington, DC; 3Womack Army Medical Center,
Fort Bragg, NC; 4National Institutes of Health, Bethesda, MD.
Background: Severe renal failure requiring hemodialysis (HD)
complicates multiple myeloma (MM) in about 3% of cases. Al-
though MM is not a contraindication to chronic dialysis, survival
of MM patients on dialysis is lower than for other conditions such
as diabetes. High dose chemotherapy and autologous stem cell
transplantation (ASCT) is feasible and effective in MM patients
on HD based on small, single center studies. Methods: We con-
ducted a retrospective cohort study of U.S. Medicare primary payer
dialysis patients with multiple myeloma as cause of end stage renal
disease in the U.S. Renal Database System (USRDS) from January
1999 through December 2004 with follow-up through September
2005. Medicare claims for ASCT were based on ICD-9 codes. Lo-
gistic regression was used to assess factors independently associated
with ASCT. Cox time-dependent regression was used to test
whether ASCT was independently associated with survival in this
cohort. Results: There were 3,307 MM patients, of whom 48
(1.5%) underwent ASCT. The mean age of ASCT patients was
60.9 yrs compared to 72.2 yrs in non-ASCT patients (p\ 0.001).
Factors that favored receiving ASCT by logistic regression were:
younger age, higher serum albumin, lower hematocrit and more re-
cent initiation of HD. Factors associated with survival (adjusted
hazard ratios with 95% CI) include ASCT (0.598, 0.352–1.017), Af-
rican-American (0.866, 0.777–0.964), albumin (0.86, 0.804–0.919),
hematocrit, (0.987, 0.979–0.995), age (1.017, 1.012–1.022), and
year of HD initiation, (0.848, 0.822–0.875). The 2-year survival
for ASCT patients was 67.4% and for non-ASCT patients was
24.5%. Conclusions: MM patients on HD rarely undergo
ASCT. The survival of MM patients on HD who do not receive
a transplant is poor. The survival of MM patients on HD who un-
dergo ASCT appears comparable to non-HD patients. Hemodialy-
sis should not be an absolute contraindication to ASCT in MM.170
LONG-TERM OUTCOME OF NONMYELOALATIVE ALLOGRAFTING FROM
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Background: Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative conditioning may be used
with lower transplant-related mortality (TRM) in elderly patients
(pts) and/or those with comorbidities. In this approach anti-tumor
activity relies on graft-versus-tumor effects. Here we analyzed out-
comes of nonmyeloablative allografts from HLA-identical sibling
performed by a multicenter consortium in pts with multiple mye-
loma (MM) with a median follow up (FU) of 5 years(y). Patients:
Between March 1998 and February 2007, 133 pts with stage II-III
MM received alloHCT following 2 Gy TBI 1/- fludarabine (48/
133 pts). Median age was 52 (range 31–71) y. Forty-eight and 7
pts (36% and 5%) were older than 55 and 65 y, respectively, and
43% had HCT specific comorbidity scores .1. Median number
of prior treatments was 1(range 1–6) and 44 pts (33%) received 2
or more lines of therapy. One hundred two pts (77%) received their
allografts as consolidation following cytoreductive autografts (con-
ditioning in 97% of pts: melphalan 200 mg/m2). Postgrafting im-
munosuppression was mycophenolate mofetil (MMF) and
cyclosporine (n5 116, 87%) or tacrolimus (n5 17, 13%). At allog-
rafting 86 pts (65%) had chemoresponsive disease with 33 and 53
pts (25% and 40%) in complete (CR) and partial remission (PR), re-
spectively, while 32 and 15 pts (24% and 11%) had chemorefractory
and progressive disease respectively. Results: Median FU for sur-
viving pts was 5(range 0.3–8.5)y. Fifty four(41%) and 12 pts (9%)
had grade 2 to 4 and 3 to 4 acute graft-versus-host-disease
(GVHD); 86 pts (65%) had extensive chronic GVHD. The overall
response rate was 89%, with 73(55%) and 46(34%) pts achieving
CR and PR, respectively. Median time to progression was 3.6 y. Me-
dian progression-free survival (PFS) was 2.7 y, and 5-y estimated
PFS was 28%. Nonrelapse mortalities (NRM) at 100 days, 1 and
5 y were 1%, 13% and 24%. Median overall survival (OS) was
reached after 6.2 y, and 5-y estimated OS was 54%. In the subset
of 102 pts who received a tandem auto/allografts, the median time
to progression was 4 y, median PFS was 3 y while median OS has
not been reached. In this group estimated PFS and OS at 3 and 5-
years were 69% and 40%, 80% and 55% respectively. Conclusion:
Nonmyeloablative allografting, in particular as part of a planned
tandem auto/allo HCT protocol, is a treatment option for MM
pts with HLA identical siblings. Future studies are aimed at improv-
ing long-term disease control and reducing GVHD.171
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS CU-
RATIVE POTENTIAL FOR CHEMOREFRACTORY NON-HODGKIN LYM-
PHOMA
Kato, K., Krijanovski, O., Khaled, Y., Peres, E., Reddy, P., Choi, S.,
Kitko, C., Yanik, G., Levine, J., Ferrara, J., Mineishi, S. University of
Michigan, Ann Arbor, MI.
Background: Autologous hematopoietic stem cell transplanta-
tion (auto-HSCT) has been widely used in patients with relapsed
chemosensitive non-Hodgkin lymphoma (NHL), but the prognosis
of patients with chemorefractory NHL remains poor. We com-
pared our experience of allo-HSCT with auto-HSCT for patients
with NHL.Methods: A total of 377 patients with NHL underwent
allo-HSCT (n 5 172, median age: 49 years old, range 18–71) or
auto-HSCT (n 5 205, median age: 56 years old, range 3–71) be-
tween 1996 and 2006 at University of Michigan. Patients who un-
derwent allo-HSCT for relapse after auto-HSCT were excluded.
Chemorefractory disease is defined as stable or progressive disease
64 Poster Session Iat transplantation.Results:NHL was classified as aggressive in 270
patients (168 diffuse large B-cell lymphoma, 58 mantle cell lym-
phoma, 44 peripheral T cell lymphoma), and as indolent in 107 pa-
tients (follicular lymphoma). In the allo-HSCT group (related
donor: n 5 122, unrelated donor: n 5 50), 141 patients (median
age: 47 years old, range 18–64) underwent full-intensity condition-
ing (FIC) and 31 (median age: 58 years old, range 44–71) reduced-
intensity conditioning (RIC). Overall survival (OS) at 5-year in
chemosensitive patients was 46.2% (95% CI, 33.1–59.3) in the
allo-HSCT group (n 5 63) and 41.0% (30.7–51.3) in the auto-
HSCT group (n 5 176). OS in chemorefractory patients was
35.0% (5-year OS, 25.2–44.8) with survival plateau in the allo-
HSCT group (n 5 109) but only 7.4% (4-year OS, 0–20.3) in the
auto-HSCT group (n 5 29). In multivariate analysis using a Cox
hazard model for the entire cohort, chemorefractory disease (Haz-
ard ratio [HR], 1.73; 95%CI, 1.25–2.39; p5 0.001) and age over 50
(HR, 1.57; 95%CI, 1.19–2.07; p 5 0.001) were identified as signif-
icant risk factors on progression-free survival (PFS). In chemore-
fractory indolent NHL, patients with RIC had a better outcome
than auto-HSCT (p 5 0.016) or FIC (p 5 0.083), with 5-year
PFS of 56.1% (26.2–86.0) in RIC, 0% in auto-HSCT and 20.4%
(2.6–38.2) in FIC. Conclusions: Allo-HSCT has curative potential
for patients even in chemorefractory NHL. RIC for indolent NHL
provided significant PFS for patients even with chemorefractory
disease, and merits further investigation.172
PHASE I STUDY OF VACCINATIONWITH DENDRITIC CELLMYELOMA FU-
SIONS
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We have developed a cancer vaccine in which patient derived my-
eloma cells are fused with autologous dendritic cells (DCs). In this
way, multiple tumor antigens are presented in the context of DC de-
rived costimulatory molecules. We are conducting a phase I trial in
which multiple myeloma (MM) patients undergo serial vaccination
with DC/myeloma fusions in conjunction with GM-CSF. To date,
16 patients have been enrolled and 15 have undergone therapy. Pa-
tients underwent leukapheresis and DCs were generated from ad-
herent mononuclear cells cultured for 5 days with GM-CSF and
IL-4 and matured by exposure to TNFa. The mean yield of DCs
was 1.23  108 cells with a mean viability of 88%. Patient derived
MM cells were isolated from bone marrow aspirates. The mean
yield of MM cells was 92.5  106 cells with a mean viability of
90%. Fusion cells were generated by coculture of DCs with MM
cells in the presence of polyethylene glycol. Fusion cells were quan-
tified by determining the percentage of cells that co-expressed
unique DC and MM antigens. Mean fusion efficiency and viability
was 40% and 84%, respectively. As a measure of immunologic po-
tency, DC/MM fusions stimulated allogeneic T cell proliferation,
with mean stimulation indexes of 48, 36, and 9 for the DC, fusion
and MM cell populations, respectively. To date, 15 patients have
completed vaccination at a dose of 1–5  106 fusion cells. Adverse
events potentially related to vaccine included injection site reac-
tions, edema, rash, fever, chills, fatigue, myalgias, pruritis, and diar-
rhea. 1 patient with a history of deep venous thrombosis (DVT)
developed a DVT and pulmonary embolus of uncertain relation
to the vaccine. To date, 6/9 evaluable patients have demonstrated
immunologic response, defined by at least 2 fold increase in IFNg
expression by CD4 and/or CD8 T cells in response to ex vivo expo-
sure to autologous tumor lysate. Vaccination was associated with an
increase in circulating tumor specific T cells as evidenced by an in-
crease in CD81 cells binding the MUC1 tetramer. Humoral im-
mune responses are being assessed by SEREX analysis. 3 patients
have ongoing stable disease at 3.5, 6, and 19 months following their
initial vaccine. 6 patients demonstrated disease stability with subse-
quent progression ranging from 9 weeks to 8 months following their
first vaccine. Vaccination with DC/MM fusions has been well toler-
ated, associated with immunologic response, and disease stabiliza-
tion in a majority of patients with MM.173
STEM-CELL COLLECTION PRIOR TO AUTOLOGOUS STEM CELL TRANS-
PLANTATION IS IMPROVED BY CYCLOPHOSPHAMIDE IN LENALIDO-
MIDE-TREATED PATIENTS WITH MULTIPLE MYELOMA
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Introduction: Recent studies discuss difficulty in collecting stem
cells in multiple myeloma (MM) patients receiving lenalidomide-
based induction therapy using filgastrim (granulocyte-colony stim-
ulating factor [G-CSF]) in preparation for autologous stem cell
transplantation (ASCT). It has also been suggested that treatment
time beyond 4–6 cycles might hinder collection yields. Aim: To de-
termine if addition of cyclophosphamide (CTX) to G-CSF as a mo-
bilization regimen could rescue collection of adequate stem cells for
at least two ASCTs in patients who had induction therapy with the
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/Dexa-
methasone) regimen. Method: Each 28-day cycle, patients re-
ceived: clarithromycin 500 mg po BID for days 1–28,
lenalidomide 25 mg po daily for days 1–21, and dexamethasone
40 mg po weekly on days 1, 8, 15, and 21. Patients were treatment
naive, with Stage II or III MM by Durie-Salmon criteria. Prior to
stem cell mobilization, BiRD therapy was held for a minimum of
14 days. Stem cell collection was performed after either G-CSF
alone at a dose 10 mcg/kg/day for 5–10 consecutive days until a total
of 10  106/kg CD341 stem cells had been collected, or with addi-
tion of CTX at a dose of 3 g/m2 once prior to initiation of G-CSF
therapy. Results: 28 patients underwent stem cell collection. Stem
cell mobilization was attempted with G-CSF alone in 9 instances,
and with CTX1G-CSF in 20 instances (1 patient underwent mobi-
lization with both). In comparison with G-CSF alone, CTX1G-
CSF yielded a significantly greater stem cell collection (mean
CD341 cells collected: 3.78  106/kg vs. 32.33  106/kg, P \
0.0001). Only 33% of patients who attempted stem cell mobiliza-
tion with G-CSF alone obtained sufficient CD341 cell yield vs.
100% of the patients mobilized with CTX1G-CSF (P\ 0.0001).
The extent of BiRD therapy prior to stem cell mobilization ranged
from 2–27 cycles. The number of cycles of BiRD did not signifi-
cantly impact the success rate of stem cell collection (P 5 0.14).
Conclusion: The patients mobilized with CTX1G-CSF had
a higher collection of CD341 cells, and enough stem cells for
two ASCTs were harvested from them. There was no association
between duration of BiRD therapy and successful CD341 cell col-
lection. Thus, lenalidomide-based induction therapy can be contin-
ued until desired tumor reduction goal is achieved, and CTX in
addition to G-CSF should be used to ensure successful stem cell
harvest prior to ASCT.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE
CELL LYMPHOMA
Mahindra, A., Copelan, E., Bolwell, B., Rybicki, L., Dean, R.,
Kalaycio, M., Sobecks, R., Ferraro, C., Cherni, K., Pohlman, B.,
Sweetenham, J. Cleveland Clinic, Cleveland, OH.
Background: Mantle cell lymphoma (MCL) is associated with
disappointing results with conventional chemotherapy. The use of
high dose therapy and ASCT for this disease is unclear. We report
here our experience with 61 MCL patients (pts) treated with ASCT.
Patients andMethods: 61 pts underwent ASCT for MCL between
7/1996 and 3/2007 using a uniform preparative regimen of busul-
fan, cyclophosphamide and etoposide. 51 pts (84%) had Stage IV
disease. 48% of the pts were in first complete remission (CR1),
5% were in CR2, 25% in first partial remission (PR1), 10% in
PR2 and remaining were CR/PR 31. Results: Median age at diag-
nosis was 56 yrs (range 33–71) and at transplant was 59 yrs (range
34–72). Median time from diagnosis to ASCT was 8.3 months
(range 4.6–81). There were no deaths within 100 days of ASCT.
23 pts (38%) relapsed after ASCT at a median of 19.8 months (range
2.6–59.6). On multivariable analysis, patients transplanted in CR2
or PR2 compared to CR1 or PR1 (p\0.001, HR 5.72) had a higher
risk of relapse.
